Page last updated: 2024-11-05

tranexamic acid and Chronic Lung Injury

tranexamic acid has been researched along with Chronic Lung Injury in 3 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Research Excerpts

ExcerptRelevanceReference
"Intravenous tranexamic acid (TXA) is an effective adjunct after hemorrhagic shock (HS) because of its antifibrinolytic properties."7.83Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. ( Ban, K; Kozar, RA; LeBlanc, A; Peng, Z, 2016)
"This series demonstrates successful bleeding management with nebulized tranexamic acid, reducing the frequency of ECMO circuit changes, time off of anticoagulation and blood loss."4.12A role for nebulized tranexamic acid in veno-venous ECMO patients. ( Ahmed, S; Cabanilla, MG; Villalobos, NE, 2022)
"Intravenous tranexamic acid (TXA) is an effective adjunct after hemorrhagic shock (HS) because of its antifibrinolytic properties."3.83Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. ( Ban, K; Kozar, RA; LeBlanc, A; Peng, Z, 2016)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Cabanilla, MG1
Villalobos, NE1
Ahmed, S1
Peng, Z1
Ban, K1
LeBlanc, A1
Kozar, RA1
Furst, W1
Banerjee, A1
Redl, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630]Phase 3130 participants (Anticipated)Interventional2024-03-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for tranexamic acid and Chronic Lung Injury

ArticleYear
A role for nebulized tranexamic acid in veno-venous ECMO patients.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:1

    Topics: Administration, Inhalation; Adult; Aged; Antifibrinolytic Agents; Extracorporeal Membrane Oxygenatio

2022
Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock.
    The journal of trauma and acute care surgery, 2016, Volume: 81, Issue:2

    Topics: ADAM17 Protein; Animals; Enzyme-Linked Immunosorbent Assay; Inflammation; Intestinal Mucosa; Intesti

2016
Comparison of structure, strength and cytocompatibility of a fibrin matrix supplemented either with tranexamic acid or aprotinin.
    Journal of biomedical materials research. Part B, Applied biomaterials, 2007, Volume: 82, Issue:1

    Topics: Animals; Antifibrinolytic Agents; Aprotinin; Fibrin; Fibrin Tissue Adhesive; Lung Injury; Materials

2007